Security
EDVA · Endovia Health Sciences, Inc.
EDVANYSE_AMERICANCommon stockCurrentCIK 1553788Updated Sep 26, 2026
Name history
SPLASH BEVERAGE GROUP, INC. · through Aug 21, 2026Canfield Medical Supply, Inc. · through Aug 5, 2020
EDVA price & chart
Loading TradingView…
AMEX:EDVA on TradingView ↗About the company
Splash is a Nevada corporation that was historically seeking to identify, acquire, and build early stage or under-valued beverage brands that have strong growth potential within its distribution system. During the current fiscal year beginning January 1, 2026, Splash has moved away from beverages and is focusing on the cannabinoid and wellness economy businesses.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
PRE 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
PRE 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Unregistered Sales of Equity Securities
Items 3.02
424B3 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
EFFECT filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 965,694Source | 2,759,185Source | 9,898,768Source | 17,304,703Source |
| Property, Plant and Equipment, NetUSD | 12,926Source | 204,808Source | 349,802Source | 489,597Source |
| GoodwillUSD | — | — | 256,823Source | 256,823Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 281,435Source | 15,346Source | 379,978Source | 4,431,745Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 15,748Source | 396,855Source | 890,631Source | 1,812,110Source |
| Inventory, NetUSD | 33,538Source | 893,061Source | 2,252,469Source | 3,721,307Source |
| Assets, CurrentUSD | 631,993Source | 1,904,119Source | 3,977,248Source | 10,657,574Source |
| Operating Lease, Right-of-Use AssetUSD | 48,041Source | 351,336Source | 556,140Source | 750,042Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 16,266,522Source | 21,394,034Source | 15,504,094Source | 7,982,569Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,998Source | 1,670Source | 44,330Source | 41,086Source |
| Additional Paid in CapitalUSD | 166,561,278Source | 137,114,578Source | 127,701,710Source | 121,632,547Source |
| Retained Earnings (Accumulated Deficit)USD | -181,899,055Source | -155,832,277Source | -133,334,783Source | -112,331,027Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 33,828Source | 81,180Source | -16,583Source | -20,472Source |
| Stockholders' Equity Attributable to ParentUSD | -15,300,828Source | -18,634,849Source | -5,605,326Source | 9,322,134Source |
| Liabilities and EquityUSD | 965,694Source | 2,759,185Source | 9,898,768Source | 17,304,703Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,260,128Source | 19,369,242Source | 14,750,310Source | 4,965,584Source |
| Operating Lease, Liability, CurrentUSD | 50,720Source | 305,167Source | 262,860Source | 268,749Source |
| Accounts Payable, CurrentUSD | 4,810,061Source | 5,232,241Source | 4,444,286Source | 3,383,187Source |
| Operating Lease, Liability, NoncurrentUSD | 2,976Source | 53,697Source | 296,128Source | 480,666Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | 13,683Source |
| Deferred Tax Liabilities, NetUSD | 235,827Source | 145,467Source | 120,502Source | 93,476Source |
| Dividends Payable, CurrentUSD | 831,944Source | — | — | — |
| Long-term DebtUSD | 3,418Source | 1,971,095Source | 457,656Source | 2,536,319Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -25,282,186Source | — | — | -21,710,941Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,623,545Source | 2,356,684Source | 1,169,858Source | 1,146,965Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -176,244Source | -493,777Source | -921,479Source | 697,658Source |
| Increase (Decrease) in InventoriesUSD | -285,566Source | -1,359,408Source | -1,468,838Source | 1,797,828Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,820,018Source | -8,003,919Source | -10,189,263Source | -14,061,116Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -3,235Source | -14,113Source | -102,698Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,104,137Source | 7,544,759Source | 6,147,720Source | 14,446,951Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 267,646Source | -364,632Source | -4,051,767Source | 250,362Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 281,435Source | 15,346Source | 379,978Source | 4,431,745Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 132,863Source | 795,022Source | 243,087Source | — |
| Income Taxes Paid, NetUSD | — | — | — | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -47,352Source | 97,763Source | 3,889Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 8,510,946Source | 2,356,684Source | 1,169,858Source | — |
| Amortization of Intangible AssetsUSD | — | 392,068Source | 392,068Source | — |
| DepreciationUSD | 148,070Source | 148,229Source | 153,908Source | 182,886Source |
| Dividends Payable, CurrentUSD | 831,944Source | — | — | — |
| Gain (Loss) on Disposition of Real Estate, Discontinued OperationsUSD | — | — | 0Source | 148,747Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | 0Source | -84,375Source |
| GoodwillUSD | — | — | 256,823Source | 256,823Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | 4,324,064Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -23,756,551Source | -21,003,757Source | -21,640,062Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -885,563Source | — | 0Source | -199,154Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | 1,991Source | 2,634Source | 6,068Source |
| Net Income (Loss) Attributable to ParentUSD | -25,234,834Source | -23,756,551Source | -21,003,757Source | -21,690,469Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -21,690,469Source |
| Operating ExpensesUSD | 14,203,118Source | 16,401,686Source | 20,855,353Source | 27,313,498Source |
| Other Nonoperating Income (Expense)USD | -10,163,051Source | -7,710,315Source | -5,717,099Source | -245,429Source |
| Other Operating Income (Expense), NetUSD | 234,996Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 11,428,591Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 73,066Source | 4,155,208Source | 18,850,152Source | 18,087,486Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -14,186,220Source | -16,046,236Source | -15,286,658Source | -21,394,633Source |
| Other Nonoperating Income (Expense)USD | -10,163,051Source | -7,710,315Source | -5,717,099Source | -245,429Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -25,234,834Source | -23,756,551Source | -21,003,757Source | -21,690,469Source |
| Earnings Per Share, BasicUSD per share | -11.97Source | — | — | — |
| Earnings Per Share, DilutedUSD per share | -11.97Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 2,178,397Source | 1,338,428Source | 42,449,631Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 2,178,397Source | 1,338,428Source | 42,449,631Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 392,068Source | 392,068Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 9,284Source | 540,297Source | 545,977Source | 936,020Source |
| Gross ProfitUSD | 16,898Source | 355,450Source | 5,568,695Source | 5,918,865Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -23,756,551Source | -21,003,757Source | -21,640,062Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -11.56Source | -17.68Source | -0.49Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -11.56Source | -17.68Source | -0.49Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -885,563Source | — | 0Source | -199,154Source |
| Interest ExpenseUSD | 2,523,260Source | 3,702,611Source | 1,856,777Source | 251,497Source |
| Interest Income (Expense), NetUSD | -2,523,260Source | -3,700,620Source | — | — |
| Investment Income, InterestUSD | — | 1,991Source | 2,634Source | 6,068Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -21,690,469Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | 22,900,000Source | 21,000,000Source | 21,700,000Source |
| Operating ExpensesUSD | 14,203,118Source | 16,401,686Source | 20,855,353Source | 27,313,498Source |
| Other IncomeUSD | — | — | — | 0Source |
| Other Operating Income (Expense), NetUSD | 234,996Source | — | — | — |
| Selling and Marketing ExpenseUSD | 79,014Source | 750,407Source | 2,493,520Source | 2,806,888Source |
Offerings
Registration 333-298112
Registration 333-296755
Registration 333-292368
Registration 333-292243
Filing attachments
e7970_ex4-1.htm · 8-K · 2026-09-24
EXHIBIT 4.1 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES FILED PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, OR (…
Read attachment ↗e7964_ex99-1.htm · 8-K · 2026-09-22
EXHIBIT 99.1 Endovia Health Sciences Closes Initial $500,000 Financing to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways Initial funding represents first tranche of previously announced $1 million C/M Capital commitment supporting CannEpil® development and commercialization Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines FORT LAUDERDALE, Fla. - September…
Read attachment ↗e7903_ex99-1.htm · 8-K · 2026-08-31
EX-99.1 2 e7903_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline Company views federal support for Schedule III as a significant evolution in U.S. cannabinoid policy and an important step toward a durable regulatory framework for cannabinoid-based medicines and wellness products Endovia expects to submit CannEpil® Z submission in the coming week and request…
Read attachment ↗e7891_ex99-1.htm · 8-K · 2026-08-25
EX-99.1 2 e7891_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program FDA establishes Investigational New Animal Drug (INAD) File No. 14145, advancing the Company’s companion-animal oncology program and marking first milestone under Lupvindol collaboration FORT LAUDERDALE, Fla., August 25, 2026 - Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverag…
Read attachment ↗e7881_ex99-1.htm · 8-K · 2026-08-21
EX-99.1 2 e7881_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday New corporate identity and ticker reflect the Company’s transformation into a diversified cannabinoid-based health sciences platform FORT LAUDERDALE, Fla., August 21, 2026 - Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its …
Read attachment ↗e7875_ex99-1.htm · 8-K · 2026-08-20
EX-99.1 2 e7875_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT LAUDERDALE, Fla., August 20, 2026 - Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ende…
Read attachment ↗